These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

503 related articles for article (PubMed ID: 15867214)

  • 61. Detecting carcinoma cells in peripheral blood of patients with hepatocellular carcinoma by immunomagnetic beads and rt-PCR.
    Guo J; Yao F; Lou Y; Xu C; Xiao B; Zhou W; Chen J; Hu Y; Liu Z
    J Clin Gastroenterol; 2007 Sep; 41(8):783-8. PubMed ID: 17700428
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Increased human telomerase reverse transcriptase (hTERT) mRNA expression but not telomerase activity is related to survival in curatively resected non-small cell lung cancer.
    Metzger R; Vallbohmer D; Müller-Tidow C; Higashi H; Bollschweiler E; Warnecke-Eberz U; Brabender J; Baldus SE; Xi H; Berdel WE; Serve H; Hoelscher AH; Schneider PM
    Anticancer Res; 2009 Apr; 29(4):1157-62. PubMed ID: 19414359
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Identification of serum anti-human telomerase reverse transcriptase (hTERT) auto-antibodies during progression to hepatocellular carcinoma.
    Masutomi K; Kaneko S; Yasukawa M; Arai K; Murakami S; Kobayashi K
    Oncogene; 2002 Aug; 21(38):5946-50. PubMed ID: 12185596
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma.
    Mizukoshi E; Nakamoto Y; Marukawa Y; Arai K; Yamashita T; Tsuji H; Kuzushima K; Takiguchi M; Kaneko S
    Hepatology; 2006 Jun; 43(6):1284-94. PubMed ID: 16729333
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Detection of alpha-fetoprotein-L3 using agglutinin-coupled spin column to be used in diagnosis of hepatocellular carcinoma].
    Sun GZ; Zhao XY; Li JH; Zhao GQ; Wang SX; Kong SL
    Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1986-8. PubMed ID: 19062741
    [TBL] [Abstract][Full Text] [Related]  

  • 66. PAI-1, t-PA and circulating hTERT DNA as related to virus infection in liver carcinogenesis.
    Divella R; Lacalamita R; Tommasi S; Coviello M; Daniele A; Garrisi VM; Abbate I; Simone G; Gadaleta C; Paradiso A; Quaranta M
    Anticancer Res; 2008; 28(1A):223-8. PubMed ID: 18383849
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Telomerase and c-myc expression in hepatocellular carcinomas.
    Liu YC; Chen CJ; Wu HS; Chan DC; Yu JC; Yang AH; Cheng YL; Lee SC; Harn HJ
    Eur J Surg Oncol; 2004 May; 30(4):384-90. PubMed ID: 15063891
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Significance of Golgi glycoprotein 73, a new tumor marker in diagnosis of hepatocellular carcinoma: a primary study].
    Mao YL; Yang HY; Xu HF; Sang XT; Lu X; Yang ZY; Zhang JC; Zhong SX; Huang JF; Zhang HB
    Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(14):948-51. PubMed ID: 18756964
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Expression of human telomerase reverse transcriptase gene in HCC does not depend on proliferating cell nuclear antigen and P53].
    Zhang D; Li KZ; Dou KF; Gao ZQ; Song ZS; Zhao QC; Fu YC
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 Nov; 20(6):721-2. PubMed ID: 15555445
    [TBL] [Abstract][Full Text] [Related]  

  • 70. AFP mRNA detected in bone marrow by real-time quantitative RT-PCR analysis predicts survival and recurrence after curative hepatectomy for hepatocellular carcinoma.
    Kamiyama T; Takahashi M; Nakagawa T; Nakanishi K; Kamachi H; Suzuki T; Shimamura T; Taniguchi M; Ozaki M; Matsushita M; Furukawa H; Todo S
    Ann Surg; 2006 Sep; 244(3):451-63. PubMed ID: 16926571
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Telomerase activity and human telomerase reverse transcriptase mRNA expression are correlated with clinical aggressiveness in soft tissue tumors.
    Tomoda R; Seto M; Tsumuki H; Iida K; Yamazaki T; Sonoda J; Matsumine A; Uchida A
    Cancer; 2002 Sep; 95(5):1127-33. PubMed ID: 12209700
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease.
    Zinkin NT; Grall F; Bhaskar K; Otu HH; Spentzos D; Kalmowitz B; Wells M; Guerrero M; Asara JM; Libermann TA; Afdhal NH
    Clin Cancer Res; 2008 Jan; 14(2):470-7. PubMed ID: 18223221
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Telomerase activity and expression of human telomerase catalytic subunit gene in esophageal tissues.
    Tominaga T; Kashimura H; Suzuki K; Nakahara A; Tanaka N; Noguchi M; Itabashi M; Ohkawa J
    J Gastroenterol; 2002; 37(6):418-27. PubMed ID: 12108675
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Serum des-gamma-carboxy prothrombin levels determined by a new generation of sensitive immunoassays in patients with small-sized hepatocellular carcinoma.
    Nomura F; Ishijima M; Kuwa K; Tanaka N; Nakai T; Ohnishi K
    Am J Gastroenterol; 1999 Mar; 94(3):650-4. PubMed ID: 10086646
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Alpha-fetoprotein and human telomerase reverse transcriptase mRNA levels in peripheral blood of patients with hepatocellular carcinoma.
    Kong SY; Park JW; Kim JO; Lee NO; Lee JA; Park KW; Hong EK; Kim CM
    J Cancer Res Clin Oncol; 2009 Aug; 135(8):1091-8. PubMed ID: 19184104
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Circulating messenger RNA of alpha-fetoprotein: a possible risk factor of recurrence after resection of hepatocellular carcinoma.
    Jeng KS; Sheen IS; Tsai YC
    Arch Surg; 2004 Oct; 139(10):1055-60. PubMed ID: 15492142
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Early diagnosis of hepatocellular carcinoma using a sensitive assay for serum des-gamma-carboxy prothrombin: a prospective study.
    Ikoma J; Kaito M; Ishihara T; Nakagawa N; Kamei A; Fujita N; Iwasa M; Tamaki S; Watanabe S; Adachi Y
    Hepatogastroenterology; 2002; 49(43):235-8. PubMed ID: 11941963
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Expression of SSX-1 and NY-ESO-1 mRNA in tumor tissues and its corresponding peripheral blood expression in patients with hepatocellular carcinoma.
    Lu Y; Wu LQ; Lü ZH; Wang XJ; Yang JY
    Chin Med J (Engl); 2007 Jun; 120(12):1042-6. PubMed ID: 17637219
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Study on the prognostic value of hepatocyte growth factor and c-met for patients with hepatocellular carcinoma].
    Wu FS; Zheng SS; Wu LJ; Ding W; Ma ZM; Wang ZM; Teng LS; Zhao WH
    Zhonghua Wai Ke Za Zhi; 2006 May; 44(9):603-8. PubMed ID: 16784653
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Sensitive measurement of serum abnormal prothrombin (PIVKA-II) as a marker of hepatocellular carcinoma.
    Tanaka Y; Kashiwagi T; Tsutsumi H; Nagasawa M; Toyama T; Ozaki S; Naito M; Ishibashi K; Azuma M
    Hepatogastroenterology; 1999; 46(28):2464-8. PubMed ID: 10522021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.